Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating
CEO & Managing Director, Dr Tony Keating
Source: ResApp Health
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) achieves Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application
  • The cough counter tracks cough frequency using ResApp’s machine learning algorithms that accurately identify coughs from a smartphone’s microphone
  • This technology is already being used by AstraZeneca to monitor patients participating in a lung cancer clinical trial and an asthma management support program
  • Additionally, it is now listed on the Australian Register of Therapeutic Goods and is available for sale in Europe as a class I medical device
  • Shares in ResApp are steady on the market and are trading at 5.6 cents

ResApp Health (RAP) has achieved Australian Therapeutics Good Administration clearance and CE Mark certification for its cough counter smartphone application.

The cough counter tracks cough frequency using ResApp’s machine learning algorithms that accurately identify coughs from a smartphone’s microphone.

Additionally, it is now listed on the Australian Register of Therapeutic Goods and is available for sale in Europe as a class I medical device.

ResApp’s cough counting technology is already being used by AstraZeneca to monitor patients participating in a lung cancer clinical trial and an asthma management support program.

CEO and Managing Director Dr Tony Keating is pleased to have secured regulatory clearance.

“We are pleased to have secured regulatory clearance in Australia and Europe for our cough counting technology,” Dr Keating commented.

“The ability to measure cough frequency using only a smartphone is a highly scalable solution that has a number of broad clinical applications.

“After our success in partnering with AstraZeneca, we are particularly excited about the opportunity in supporting clinical trials, where cough can provide important insight into the progressing of disease and efficacy of treatment.”

ResApp was steady on the market, with shares trading at 5.6 cents at 11:24 am AEDT.

RAP by the numbers
More From The Market Herald

" Nova Minerals (ASX:NVA) prepares for further drilling at Estelle

Nova Minerals (ASX:NVA) prepares for further resource development drilling at its Estelle Gold Project in Alaska…

" Perseus Mining (ASX:PRU) confirms resource upgrade potential at Yaouré gold mine

Perseus Mining (ASX:PRU) says latest drill results from the Yaouré gold mine in Côte d’Ivoire confirm…

" Burgundy Diamond Mines (ASX:BDM) purchases further fancy colour rough diamonds

Burgundy Diamond Mines (BDM) has signed purchase agreements with two companies to buy further fancy colour…
Danodan Hempworks LLC - Founder, Daniel Stoops

" KijiKava Ltd (ASX:FIJ) acquires Danodan Hempworks and US patent

Medicinal kava company FijiKava (ASX:FIJ) completes the acquisition of Danodan Hempworks, including its CBD extraction US…